RecruitingPhase 1

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

United States24 participantsStarted 2026-03-31

Plain-language summary

The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent.
✓. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.

What they're measuring

Number of Participants with Adverse Events (AEs)

Timeframe: Up to approximately 138 days

Trial details

NCT IDNCT07514260

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

ABBVIE CALL CENTER

844-663-3742 abbvieclinicaltrials@abbvie.com

View on ClinicalTrials.gov More Healthy Volunteer trials